Literature DB >> 33026580

Takayasu arteritis: a cohort of Italian patients and recent pathogenetic and therapeutic advances.

Franco Dammacco1, Anna Cirulli2, Annalisa Simeone3, Patrizia Leone2, Raffaele Pulli4, Domenico Angiletta4, Giuseppe Rubini5, Alessandra Di Palo5, Angelo Vacca2, Rosanna Dammacco6.   

Abstract

Takayasu arteritis (TAK) is a rare granulomatous vasculitis of unknown etiology that mainly affects the aorta and its major branches. The aim is to describe the clinical features, diagnostic procedures, pathogenesis, and management of TAK in a longitudinal cohort of patients recruited within a single region of southern Italy. The cohort included 43 patients who were diagnosed with TAK and followed up according to a standard protocol, in a collaboration between four university tertiary referral centers and a regional hospital. Clinical and imaging classification criteria were those established by the American College of Rheumatology. Thirty-five patients (81.4%) were female, and the mean age at disease onset was 32.6 (range 16-54) years. Angiographic assessment of the vascular involvement allowed disease classification in five different types. Clinical features ranged from constitutional symptoms in the early inflammatory stage of the disease to cardiovascular ischemic symptoms in the late, chronic stage. Noninvasive imaging techniques were employed to assess the extent and severity of the arterial wall damage and to monitor the clinical course and response to therapy. Medical treatment, based on pathogenetic insights into the roles of humoral and cell-mediated immune mechanisms, included glucocorticoids mostly combined with steroid-sparing immunosuppressive agents and, in patients with relapsing/refractory disease, biologic drugs. Significant clinical and angiographic differences have been detected in TAK patients from different geographic areas. Patients with life-threatening cardiovascular and neurologic manifestations as well as sight-threatening ophthalmologic signs and symptoms should be promptly diagnosed, properly treated, and closely followed up to avoid potentially severe consequences.

Entities:  

Keywords:  Biologic agents; Imaging methods; Immunosuppressive therapy; Large-vessel vasculitis; Takayasu arteritis

Year:  2020        PMID: 33026580     DOI: 10.1007/s10238-020-00668-7

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  61 in total

Review 1.  Takayasu arteritis: a review.

Authors:  S L Johnston; R J Lock; M M Gompels
Journal:  J Clin Pathol       Date:  2002-07       Impact factor: 3.411

2.  The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis.

Authors:  W P Arend; B A Michel; D A Bloch; G G Hunder; L H Calabrese; S M Edworthy; A S Fauci; R Y Leavitt; J T Lie; R W Lightfoot
Journal:  Arthritis Rheum       Date:  1990-08

Review 3.  Takayasu arteritis: challenges in diagnosis and management.

Authors:  Esther S H Kim; Joshua Beckman
Journal:  Heart       Date:  2017-11-25       Impact factor: 5.994

Review 4.  Takayasu arteritis: an update.

Authors:  Emire Seyahi
Journal:  Curr Opin Rheumatol       Date:  2017-01       Impact factor: 5.006

5.  Current Clinical Features of New Patients With Takayasu Arteritis Observed From Cross-Country Research in Japan: Age and Sex Specificity.

Authors:  Yoshiko Watanabe; Tetsuro Miyata; Kazuo Tanemoto
Journal:  Circulation       Date:  2015-09-09       Impact factor: 29.690

Review 6.  Takayasu Arteritis: Recent Developments.

Authors:  Maria L F Zaldivar Villon; Jose A Leon de la Rocha; Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2019-07-18       Impact factor: 4.592

Review 7.  EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice summary.

Authors:  Mohammad Bardi; Andreas P Diamantopoulos
Journal:  Radiol Med       Date:  2019-06-28       Impact factor: 3.469

8.  Takayasu disease on the centenary of its discovery.

Authors:  Kazuhisa Sugiyama; Shigeyuki Ijiri; Shigeki Tagawa; Koichi Shimizu
Journal:  Jpn J Ophthalmol       Date:  2009-03-31       Impact factor: 2.447

9.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Authors:  J C Jennette; R J Falk; P A Bacon; N Basu; M C Cid; F Ferrario; L F Flores-Suarez; W L Gross; L Guillevin; E C Hagen; G S Hoffman; D R Jayne; C G M Kallenberg; P Lamprecht; C A Langford; R A Luqmani; A D Mahr; E L Matteson; P A Merkel; S Ozen; C D Pusey; N Rasmussen; A J Rees; D G I Scott; U Specks; J H Stone; K Takahashi; R A Watts
Journal:  Arthritis Rheum       Date:  2013-01

10.  Elevated antistreptolysin O titer is closely related to cardiac mitral insufficiency in untreated patients with Takayasu arteritis.

Authors:  Lili Pan; Juan Du; Junming Zhu; Zhiyu Qiao; Yanlong Ren; Xinsheng Huang; Shichao Guo; Na Gao
Journal:  BMC Cardiovasc Disord       Date:  2020-02-03       Impact factor: 2.298

View more
  3 in total

Review 1.  Highlights in clinical medicine-Giant cell arteritis, polymyalgia rheumatica and Takayasu's arteritis: pathogenic links and therapeutic implications.

Authors:  Antonio Giovanni Solimando; Angelo Vacca; Franco Dammacco
Journal:  Clin Exp Med       Date:  2021-11-06       Impact factor: 5.057

2.  Arterial Stiffness and Adult Onset Vasculitis: A Systematic Review.

Authors:  Alberto Lo Gullo; Clemente Giuffrida; Carmela Morace; Giovanni Squadrito; Paola Magnano San Lio; Luisa Ricciardi; Carlo Salvarani; Giuseppe Mandraffino
Journal:  Front Med (Lausanne)       Date:  2022-05-12

3.  Takayasu's Arteritis With Acute Severe Aortic Regurgitation Requiring a Bio-Bentall Procedure.

Authors:  Polsha Jules; Oscar Valencia; Damian Valencia; Ananya Reddy; Rehan Ahmed
Journal:  Cureus       Date:  2022-07-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.